Walls @52.50
amandaviolet
Posts
-
-
Where’s the bottom here?
-
NVAX or bust! 100% IMMUNITY read the article in NEJM. I work at one of the biggest medical centers in Houston, this is the vaccine providers want/support......NEJM! NVAX will save the world & buy me a 2nd home. Buying more to furnish it
-
Nvax just got mentioned on CNBC
-
51% short volume not interest reported by shortvolumes in NVAX
The dips & dumb comments & attacks are THEM.
Do your DD and KNOW all of the institutional investors have done so as well. I am a medical provider the science is solid for this and nanoflu.
Plan to buy another 10K on these tips -
That’s some exciting AH
-
BREAKING : Novavax $NVAX to receive FDA fast track imminently.
Source: Reuters -
Novavax Awarded Department of Defense Contract for COVID-19 Vaccine
Jun 04, 2020 at 8:04 PM EDT
Download PDFboooooooom
-
Market Date Short Volume Total Volume Short Volume Ratio
2020-08-27 768,048 4,800,540 16.00% -
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu
Novavax, Inc. recently announced it will utilize the accelerated approval pathway for licensure for NanoFlu, its nanoparticle seasonal influenza vaccine candidate. The US FDA acknowledged in a recent letter that the accelerated approval pathway is available to Novavax for its NanoFlu vaccine. Novavax expects to initiate its pivotal Phase 3 clinical trial by the fall of 2019 with top-line clinical data expected in the first quarter of 2020. These immunogenicity data are expected to support a US biologics license application (BLA).
Novavax will conduct an End-of-Phase 2 meeting with the FDA in the third quarter of 2019 to discuss the proposed Phase 3 clinical trial design and other topics that will support the future BLA. The accelerated approval pathway enables Novavax to conduct a non-inferiority immunogenicity clinical trial against a licensed quadrivalent comparator, with a commitment to confirm efficacy post-licensure.
“NanoFlu’s encouraging results observed in prior clinical trials, which demonstrated improved immune responses against licensed comparators, provide us confidence in the future success of the Phase 3 clinical trial,” said Gregory M. Glenn, MD, President of Research and Development of Novavax. “The accelerated approval pathway allows us to potentially obtain U.S. licensure more expeditiously, and ideally, deliver a greatly needed improved flu vaccine, which could reduce the tremendous medical and economic burden of influenza.”
“The accelerated approval pathway, combined with the strategic partnership we announced today with Catalent Biologics, allow us to efficiently and cost effectively complete the clinical development of NanoFlu through BLA and licensure,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The Catalent deal provides an $18 million cash infusion and flexible manufacturing capacity, supported by the experienced professionals transferred from Novavax to Catalent.”
-
I’ve been following this for about a week now. same baggers, same pumpers. bulls are winning by days end!
nanoflu news on the horizon.... IMO as a healthcare provider this will revolutionize the flu vac & that’s a vaccine everyone will take. Closing strong at $150 -
This stock is so fun to watch. If you’re stressed.....go sit on Wal-mart & watch the Instacart paint dry
DKNG
WKHS
WKHS
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
NVAX
BCRX
NVAX
NVAX
NVAX
NVAX
NVAX